Loading stock data…
Cardiff Oncology (CRDF)
$0.83-0.01 (-1.34%)
Market ClosedLast close Jul 24
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cardiff Oncology, Inc. in the Healthcare sector is trading at $0.83 with a market capitalization of $93M. Wall Street consensus targets $5.21 (7 analysts), implying a +530.6% move over the next 12 months. The stock is currently near its 52-week low of $0.80, remaining 56.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +530.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 22) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $41,000↓ | $243,000↑ | $120,000↓ | $121,000↑ | $109,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.85M↓ | -$7.83M↑ | -$11.97M↑ | -$14.78M↓ | -$14.38M |
| Net Income | -$12.35M↓ | -$7.22M↑ | -$11.26M↑ | -$13.94M↓ | -$13.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treatin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$92.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-128.96%
Volume
Today's trading volume
1.19M
Recent News
Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncology program. Key Investor TakeawaysCardiff Oncology (NASDAQ:CRDF) expects to raise approximately $10 million in gross proceeds through a registered direct offering.
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list. TheFly reported on June 5 that Lucid Capital analyst Christopher Liu reduced the price target on CRDF to $4 from $10 while reaffirming a Buy rating. […]
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist
Over the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stocks with strong fundamentals and growth potential is crucial for investors seeking stability and opportunity. While "penny stocks" may sound like an outdated term, they continue to represent smaller or less-established companies that can offer significant value; we've identified three such stocks...
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar
Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company’s investigational PLK1 inhibitor onvansertib during a webinar focused on first-line RAS-mutated metastatic colorectal cancer (mCRC), a population she described as having s
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly selective polo-like kinase 1 (PLK1) inhibitor being studied in RAS-mutated metastatic colorectal cance